Source:http://linkedlifedata.com/resource/pubmed/id/18640575
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2008-7-21
|
| pubmed:abstractText |
Antithymocyte globulin (ATG) as part of conditioning regimens is known to reduce the incidence and severity of acute and chronic graft-versus-host disease (aGVHD, cGVHD). The influence of ATG on transplant-related mortality (TRM) and disease-free survival (DFS) is controversial, and may depend on the dose and timing of ATG. We retrospectively compared 2 doses of ATG-Fresenius (ATG-F) in patients undergoing matched unrelated donor allogeneic hematopoetic stem cell transplantation (HSCT) for hematologic malignancies. A dose of 60 mg/kg body weight has previously been recommended for ATG-F. All patients received cyclosporine A and short course methotrexate. ATG-F was administered at a dose of 30 mg/kg on day -1 (ATG-30 group, n = 34) or 20 mg/kg/day on days -3 to -1 (ATG-60 group, n = 49). There was no difference in time to leukocyte and platelet engraftment in the 2 groups. The incidence of aGVHD grade II-IV (50% versus 53%, P = .83) and grade III-IV (27 versus 20%, P = .60) was similar in the ATG-30 versus ATG-60 groups, respectively. There was a trend to a higher incidence of cGVHD in the ATG-30 group (59% versus 40%, P = .14). The estimated 3-year incidence of relapse was similar in the ATG-30 and ATG-60 groups (15% versus 16%, P = .84) whereas the 2-year TRM was lower for the ATG-30 group (12% versus 33%, P = 0.02), mainly because of a higher incidence of fatal infections in the ATG-60 group. This resulted in a better DFS (73% versus 51%, P = .07) for the ATG-30 group. ATG-F (30 mg/kg) administered as a single dose on day -1 may lead to better outcome in patients undergoing unrelated donor allogeneic HSCT compared to 60 mg/kg given in 3 equivalent doses. A prospective randomized study comparing these 2 doses of ATG-F is warranted.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1523-6536
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
913-9
|
| pubmed:meshHeading |
pubmed-meshheading:18640575-Adolescent,
pubmed-meshheading:18640575-Adult,
pubmed-meshheading:18640575-Antilymphocyte Serum,
pubmed-meshheading:18640575-Child,
pubmed-meshheading:18640575-Child, Preschool,
pubmed-meshheading:18640575-Dose-Response Relationship, Drug,
pubmed-meshheading:18640575-Female,
pubmed-meshheading:18640575-Graft Survival,
pubmed-meshheading:18640575-Graft vs Host Disease,
pubmed-meshheading:18640575-Hematologic Neoplasms,
pubmed-meshheading:18640575-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:18640575-Histocompatibility,
pubmed-meshheading:18640575-Humans,
pubmed-meshheading:18640575-Infant,
pubmed-meshheading:18640575-Infection,
pubmed-meshheading:18640575-Male,
pubmed-meshheading:18640575-Middle Aged,
pubmed-meshheading:18640575-Recurrence,
pubmed-meshheading:18640575-Survival Analysis,
pubmed-meshheading:18640575-Transplantation, Homologous,
pubmed-meshheading:18640575-Transplantation Conditioning
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
|
| pubmed:affiliation |
Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany. ayuketan@uke.uni-hamburg.de
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|